ASSOCIATION OF GENETIC POLYMORPHISMS IN
THE Matrix Gla Protein (MGP) GENE WITH CORONARY
ARTERY DISEASE AND SERUM MGP LEVELS
Karsli-Ceppioglu S1,*, Yazar S2, Keskin Y3, Karaca M4, Luleci NE3, Yurdun T1
*Corresponding Author: Seher Karsli-Ceppioglu, Ph.D., Department of Toxicology, Faculty of Pharmacy,
Marmara University, Tibbiye Street No. 49, İstanbul 34668, Turkey. Tel: +90-216-414-2962.
Fax: +90-216-345-2952. E-mail: seher.karsli@marmara.edu.tr
page: 43
|
|
RESULTS
Clinical Characteristics of the Participants. Table
1 presents the main characteristics of 168 subjects
and their biochemical parameters indicated as risk factors
for CAD. There were no significant differences between
glucose, triglyceride, LDL-cholesterol, HDL-cholesterol,
total cholesterol levels, estimated glomerular filtration
rates (eGFR) of CAD patients and controls (p >0.05).
Furthermore, CAD patients were isolated into subgroups as
single-vessel disease (n = 62; 55.3%), two-vessel disease
(n = 30; 26.8%) and three-vessel disease (n = 20; 17.9%).
Serum MGP concentrations were not statistically different
between CAD patients and controls (p >0.05).
Genotype Distribution of MGP SNPs and Their
Associations with CAD Risk and Biochemical Profiles.
Genotype frequencies and allele distributions of MGP SNPs
rs1800802, rs4236 and rs12304, which were in accordance
with HWE expectations, are presented in Table 2. The genotype
distributions of rs1800802, rs4236 and rs12304 SNPs were not statistically different between CAD patients and
healthy controls (p = 0.701, 0.267, 0.936, respectively).
The relation between allele distribution and CAD risk was
evaluated by multinomial logistic regression analysis and
the results are shown in Table 3. The correlation between
rs1800802, rs4236 and rs12304 alleles and CAD risk was
not statistically significant (p = 0.822, 0.121 and 0.936,
respectively). Moreover, no association was found between
the presence of single-, two-, and three-vessel disease and
MGP alleles.
The allele distributions of SNPs were further evaluated
to view the association of MGP gene variants with
clinical risk factors for CAD (Table 4). Particularly, polymorphism
rs4236 had a correlation with serum HDLcholesterol
(p = 0.049).
Associations Between MGP SNPs and Serum MGP
Levels. The difference of serum MGP levels between CAD
patients (0.82 ± 0.37 μg/L) and controls (0.87 ± 0.42 μg/L)
were not statistically significant (p >0.05) (Table 1). Serum
MGP levels demonstrated diversity related to the
rs1800802 genotype distributions in CAD patients (p =
0.019). In addition, genotype distributions of rs4236 were
associated with serum MGP levels, especially in the presence
of CAD (CAD patients p = 0.012; controls p = 0.022).
The histograms of serum MGP concentrations relative to
MGP genotypes are shown in Figure 2. The eGFR profiles
of subjects were correlated with serum MGP levels (p =
0.015) (Table 4).
Haplotype Analysis and Associations Between
Haplotypes and CAD Risk, and Serum MGP Levels.
Linkage disequilibrium block structures of MGP SNPs
were performed by Haploview [12]. Linkage disequilibrium
was not observed in rs1800802, rs4236 and rs12304
and their D’ values were under 0.99. Figure 3 presents
the LD block structures and their association with CAD
risk. At the haplotype analysis, there was no correlation
between three haplotypes and CAD risk. Furthermore,
serum MGP concentrations showed no difference related
to these haplotype distributions, according to multinomial
logistic regression analysis.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
